Investors

Board of directors

According to the articles of association Immunicum AB (publ)’s (the “Company”) board of directors shall consist of at least three (3) and at most eight (8) board members without deputies. The Company’s board of directors currently consists of seven (7) board members, including the chairman of the board of directors. All board members have been appointed until the end of next annual general meeting. Information regarding the Company’s board members, including year of birth, education and experiences, year of election to the board of board members, ongoing engagements and past engagements during the past five (5) years and shareholding in the Company (including indirect holdings and related persons’ holdings), can be found below.

  • Michael Oredsson

    Chairman since 2018

    Shares: 17 560 MSc in International Business Administration Born: 1960

    Experience: Michael Oredsson was until the end of 2017 CEO of publically-listed Bioinvent. Prior to that, Michael was CEO of Probi (2007-2013), Biosignal in Australia (2002-2007) and Nutripharma in Norway (1999-2001). During the eighties and nineties, he worked in senior positions in companies such as Pharmacia, M & M/Mars and Nestlé.

    Ongoing engagements: Michael is currently CEO and board member of Biome Australia Ltd (Melbourne). CEO and Board member of NLSC – Northern Lights Southern Cross AB.

    Independency: Michael Oredsson is independent in relation to the company, its senior executives and major shareholders.

  • Charlotte Edenius

    Board member since 2016

    Shares: 4000 M.D., Ph.D., Karolinska Institute, Stockholm Born: 1958

    Experience: Charlotte Edenius has more than 20 years of experience from senior executives in pharmaceutical- and biotech companies, including experience from development of pharmaceuticals, regulatory issues and marketing. Charlotte has previously worked as Executive Vice President (R&D) at Medivir AB, Senior Vice President (R&D) at Orexo AB and as Vice President Research at Biolipox AB and various positions within clinical research and development at AstraZeneca.

    Ongoing engagements: Chairman of the board of directors and CEO of Allmora Life Science AB. Board member of Kancera AB, SynAct Pharma AB and Gesynta Pharma AB.

    Past engagements during the last five (5) years: Board member of Karolinska Institutet Innovations AB, Karolinska Development AB and Qlucore AB.

    Independency: Charlotte Edenius is independent in relation to the company, its senior executives and major shareholders.

  • Magnus Persson

    Magnus Persson

    Board member since 2015

    Physician and an associate Professor in Physiology at the Karolinska Institutet in Stockholm Born: 1960

    Experience: Magnus Persson has 15 years’ experience as a partner in Venture Capital and has been partner in two Life Science Venture Capital companies, one based in Sweden but with global scope and one based in The Bay Area in California, USA. Magnus has extensive experience of financing within medicine, Life Science and biotechnology. He has been leading development teams in phase II and III-programs within the pharmaceutical industry. He has founded and lead both private and public biotech and medtech companies, as chairman of the board of directors and as board member in Europe and the USA. He has more than 90 years’ combined experience of board service within the Life Science industry and has been involved in tens of IPO’s.

    Ongoing engagements: Chairman of the board of directors of SLS Invest AB, Attgeno AB, Addi Medical AB, Addi Optioner AB, Galecto Biotech AB, CANTARGIA AB and Perma Ventures AB. Board member of Karolinska Development AB, Gyros Protein Technologies Holding AB and Själbådan AB.

    Past engagements during the last five (5) years: Chairman of the board of directors of Bio-works Technologies AB. Board member of Gyros Protein Technologies AB.

    Independency: Magnus Persson is independent in relation to the company, its senior executives and major shareholders.

  • Steven Glazer

    Board member since 2016

    MD, University of Copenhagen and trained in Internal Medicine. Born: 1948

    Experience: Steven Glazer is an experienced executive within health and biotech. He has extensive and broad experience from the therapeutic field, including hematology, oncology, hemophilia, HIV, diabetes, allergies and cardiovascular diseases from pharmaceutical and biotech companies in Europe and the USA. He has qualifications from successful planning and implementation of development strategies, regulatory strategies and business strategies, projects and study plans. Steven is Chief Medical Officer at Hansa Medical AB and has been working as Senior Vice President Development at BioInvent, Vice President Development at Zealand Pharma and Medical Director at Novo Nordisk.

    Ongoing engagements: – Medical director of RhoVac AB. Chief Medical Officer of Idogen AB:

    Past engagements during the last five (5) years: –

    Independency: Steven Glazer is independent in relation to the company, its senior executives and major shareholders.

  • Kerstin Valinder Strinnholm

    Board member since 2016

    Degree from the School of Journalism at the University of Gothenburg. Born: 1960

    Experience: Kerstin Valinder Strinnholm is a business advisor within pharmaceuticals and biotechnology and a graduate from the School of Journalism at the University of Gothenburg. Kerstin has over 30 years of international experience within sales, marketing and business development from senior positions within Astra/AstraZeneca and Nycomed Takeda.

    Ongoing engagements: Board member of Corline Biomedical AB, Camurus AB, KVS Invest AB, Klifo A/S, Gedea Biotech AB and Cavastor AB.

    Past engagements during the last five (5) years: –

    Independency: Kerstin Valinder Strinnholm is independent in relation to the company, its senior executives and major shareholders.